CD274 and gastric cancer: Furthermore, a study involving 61 Korean patients with advanced GC treated with pembrolizumab revealed a significantly higher objective response rate in PD-L1-positive patients (50%) than in PD-L1 negative patients (0%).34 This emphasises the potential benefits of using PD-L1 expression as a biomarker for ICI treatment in EBVaGC.